CAR T-Cell Therapy

Panelists discuss how CAR T therapy represents the best curative option for relapsed B-cell lymphoma and how community oncologists must prepare for the inevitable expansion of cellular therapies across multiple disease areas.

Panelists discuss how expanding CAR T to more community sites requires adequate volume, intensive care unit support, and subspecialty backup, while recognizing that not every center should administer this therapy.

Panelists discuss how community practices need better systems for disseminating CAR T care guidelines to all team members and clearer vaccination schedules for patients post CAR T.

Taylor Brooks, MD, discusses ways that the availability of CAR T-cell therapies has augmented the relapsed/refractory LBCL treatment paradigm.

Arlo-cel achieved a high ORR and CR rate with durable responses and favorable safety in relapsed/refractory multiple myeloma.

Aaron Gerds, MD, MS, discusses the role of BTK inhibitors in CLL, real-world data with CAR T-cell therapies in LBCL, and JAK inhibitors for myelofibrosis.

Panelists discuss how the timing of community transition depends on ongoing toxicities and patient comfort levels, with continued communication essential for managing lingering effects like cytopenias and autonomic dysfunction.

Panelists discuss how the extremely rare risk of T-cell malignancies after CAR T therapy should be contextualized against the certain mortality risk of untreated refractory lymphoma.

Taylor Brooks, MD, discusses the effects of CAR T-cell therapy on LBCL management and the efficacy of axi-cel for patients with relapsed/refractory LBCL.

Panelists discuss how CMV monitoring should be implemented for patients who received extensive corticosteroids and how persistent cytopenias beyond 6 months warrant bone marrow evaluation.

Panelists discuss how community oncologists should manage long-term CAR T complications, including hypogammaglobulinemia, cytopenias, and opportunistic infections while maintaining communication with treating centers.

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.

A mogamulizumab-based combination led to complete remission in a patient with CAR-positive T-cell lymphoma with CCR4 overexpression.

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

Panelists discuss how preventive strategies like dexamethasone can reduce high-grade toxicities in high-risk patients while prophylactic tocilizumab is avoided due to increased neurotoxicity risk.

Panelists discuss how acute CAR T toxicities follow predictable patterns based on specific products, with cytokine release syndrome typically preceding neurotoxicity and inflammatory markers serving as early indicators.

Samir Parekh, MBBS, discusses monitoring rare CAR T-cell complications, anti-CCR4 therapy, and future research to improve safety and prevent secondary cancers.

The in vivo CAR T-cell therapy UB-VV111 has received fast track designation from the FDA for the management of relapsed/refractory LBCL and CLL.

A preview of the hematologic oncology abstracts and presentations to watch at the 2025 ESMO Congress in Berlin.

Panelists discuss how the dissolution of REMS requirements and availability of outpatient CAR T therapy have significantly improved access by reducing monitoring restrictions and caregiver requirements.

Panelists discuss how community oncologists can overcome misconceptions about CAR T toxicity by understanding that the therapy has evolved to be safer, with shorter hospital stays and better outcomes.

Saurabh Dahiya, MD, FACP, discussed how the unique mechanism of action of KITE-363 may improve upon the efficacy of other CAR T-cell therapies for LBCL.

Panelists discuss how community oncologists should navigate referral processes to academic centers and balance CAR T therapy against other emerging treatments like bispecific antibodies based on curative potential.

Panelists discuss how earlier referrals for CAR T therapy led to better outcomes due to healthier T cells, reduced need for bridging therapy, and improved survival benefits demonstrated in clinical trials.